Approval · Notice of Compliance 18011 · 2016
BLEXTEN: Notice of Compliance 18011
Issued April 21, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18011
- Date
- April 21, 2016
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BLEXTEN | 02454130 | Marketed |
Medicinal ingredients
- BILASTINE 20 MG per TAB